Homepage > Company > Media > Pharma News > 2022 > Dr Reddy’s launch generic version of Nexavar (sorafenib) Tablets, 200 mg in US

Dr Reddy’s launch generic version of Nexavar (sorafenib) Tablets, 200 mg in US

Dr Reddy’s Laboratories announced the launch of Dr Reddy’s Sorafenib Tablets, USP, 200 mg, a therapeutic generic equivalent of Nexavar (sorafenib) Tablets in the US market following the approval by the US Food and Drug Administration (USFDA).

“We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients,” says Marc Kikuchi, CEO, North America Generics, Dr Reddy’s Laboratories.

Dr Reddy’s Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.

Sorafenib is a kinase inhibitor indicated for the treatment of unresectable hepatocellular carcinoma and locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment.

Jun 14, 2022

https://www.expresspharma.in/

Read also

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Pfizer’s antibiotic combination, Emblaveo (aztreonam-avibactam), has been approved by the European Commission (EC) to treat patients with multidrug-resistant infections.

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva; N-803) in combination with Bacillus Calmette–Guérin (BCG) for the treatment of adult patients with BCG-unresponsive ...

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label ...

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

Ipsen and Skyhawk Therapeutics have announced an exclusive worldwide collaboration aimed at advancing RNA-targeting therapies for rare neurological diseases, with the deal worth more than $1.8bn.